Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: CD101 vs Fluconazole in Acute VVC
NCT02733432Phase 2Completed
- Sponsor
- Cidara Therapeutics
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezafungin in vulvovaginal candidiasis (VVC), sponsored by Cidara Therapeutics. Started Jun 2016; status: completed.
02
Drugs
rezafungin
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT02733432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733432.